Rybrevant Combo Resets Survival in EGFR Lung Cancer
Johnson & Johnson’s amivantamab plus lazertinib delivered a statistically significant overall survival advantage over osimertinib monotherapy in first-line EGFR-mutated...
Hinge Bio Expands Leadership for Gem-Dimer Development
Hinge Bio has expanded its leadership bench and unveiled peer‑reviewed preclinical data for HB2198, a dual‑Fc, anti‑CD19/CD20 bispecific antibody...
Mosliciguat Gains Orphan Drug Designation in Japan for PH-ILD
Japan’s Ministry of Health, Labour and Welfare has granted orphan drug designation to mosliciguat, Pulmovant’s once-daily, inhaled soluble guanylate...
Syndax Reports Inducement Grants Under Nasdaq Listing Rule
Syndax Pharmaceuticals has granted inducement stock options to purchase 167,400 shares of common stock to 11 new employees under...
Adarx Pharmaceuticals to Present at Global Health Conference
Adarx Pharmaceuticals will present at the Morgan Stanley Global Healthcare Conference on September 9, 2025, with its chief executive...
C4 Therapeutics Reveals Surging Biogen Partnership Achievement
Biogen’s investigational new drug application for BIIB142, an oral degrader of IRAK4 for autoimmune diseases, has been accepted by...
Mesoblast Enters Option for $50M Convertible Notes
Mesoblast has secured an option to raise to $50 million via unsecured convertible notes from SurgCenter principals and two...
Radiance Biopharma Inks Exclusive ‘First in Class’ ADC Deal
Radiance Biopharma has secured an exclusive ex-China license to develop and commercialize RB-601 (KY-0301), a bispecific nanobody antibody-drug conjugate...
Arcutis’ Zoryve: A Promising New Hope for Kids’ Psoriasis
Arcutis has submitted a supplemental new drug application to the FDA seeking to expand Zoryve (roflumilast) cream 0.3% for...
BioNTX Summit Spotlights 2025 Healthcare Rising Stars
BioNTX has named its 2025 Rising Stars—eight early- and growth-stage companies spanning diagnostics, therapeutics, delivery platforms, and surgical technologies—to...